“P083 | EFFECT OF ATOGEPANT ON COGNITIVE FUNCTION FOLLOWING ACUTE TREATMENT OF MIGRAINE ACROSS MULTIPLE ATTACKS: RESULTS FROM THE ECLIPSE TRIAL: R. Masselli1, A. Van Dycke­­2, G. Ahmadyar3, E. Brand-Schieber3, C. Castro3, R. Ornello4, L. Luo3, P. Pozo-Rosich5|6, U. Reuter7|8, K. Carr3, R. Gil-Gouveia9|10 | 1AbbVie Srl, Rome, Italy; 2Department of Neurology, General Hospital Sint-Jan Bruges, Belgium; 3AbbVie Inc. North Chicago, IL, USA; 4Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; 5Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain; Headache and Neurological Pain Research; 6Headache and Neurological Pain Research Group, Vall d’Hebron Institute of Research, Universitat Autonoma de Barcelona, Spain; 7University Hospital Bonn, Germany; 8Charité Universitätsmedizin Berlin, Germany; 9Neurology Department, Hospital da Luz, Lisboa, Portugal; 10Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisboa, Portugal” (2026) Confinia Cephalalgica, 36(s1). doi:10.4081/cc.2026.16039.